Baylor Miraca Genetics Laboratories, LLC v. Thomas Brandon Perthuis

CourtCourt of Appeals of Texas
DecidedDecember 3, 2020
Docket01-19-00095-CV
StatusPublished

This text of Baylor Miraca Genetics Laboratories, LLC v. Thomas Brandon Perthuis (Baylor Miraca Genetics Laboratories, LLC v. Thomas Brandon Perthuis) is published on Counsel Stack Legal Research, covering Court of Appeals of Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Baylor Miraca Genetics Laboratories, LLC v. Thomas Brandon Perthuis, (Tex. Ct. App. 2020).

Opinion

Opinion issued December 3, 2020

In The

Court of Appeals For The

First District of Texas ———————————— NO. 01-19-00095-CV ——————————— BAYLOR MIRACA GENETICS LABORATORIES, LLC, Appellant V. THOMAS BRANDON PERTHUIS, Appellee

On Appeal from the 80th District Court Harris County, Texas Trial Court Case No. 2017-16991

MEMORANDUM OPINION

Appellant Baylor Miraca Genetics Laboratories, LLC, (BMGL) employed

appellee Thomas Brandon Perthuis as Vice President of Sales and Marketing and

agreed to pay him a 3.5% commission on his net sales. BMGL terminated Perthuis

in January 2017, and Perthuis then sought a commission based on sales BMGL made after January 2017. The jury found that BMGL breached the commission

agreement, and the trial court rendered judgment on the jury verdict. BMGL

appeals, arguing in multiple issues that the trial court erred (1) in construing the

commission agreement and in charging the jury; (2) in excluding evidence of its

commission policy and practice; and (3) in the alternative, that no evidence

supported the jury’s findings. In a cross-appeal, Perthuis argues in his sole issue

that the trial court erred in denying his request for attorney’s fees under Civil

Practice and Remedies Code Chapter 38.

Because we conclude that the trial court erred in construing the commission

agreement and in instructing the jury, we reverse the judgment of the trial court

and render judgment that Perthuis take nothing.

Background

Perthuis was a National Sales Manager for Baylor College of Medicine’s

genetics lab when, in late 2014, Baylor College of Medicine entered a joint venture

with Miraca Holdings, Inc. to form a new entity to conduct clinical genetics

diagnostic activities. In connection with the joint venture, the newly formed entity,

Baylor Miraca Genetics Laboratories (BMGL), offered Perthuis the position of

Vice President of Sales & Marketing. Regarding compensation, the Employment

Offer Letter stated:

Your annual base salary will be $145,000 effective April 1, 2015. Your commission will be 3.5% of your net sales. . . . In addition, you

2 will be eligible to receive a retention bonus. More information on your retention bonus is included in the enclosed Retention Agreement.

The offer further stated that Perthuis’s employment would be “at-will,” “which

means that you or BMGL may terminate your employment at any time for any

reason, with or without cause, and with or without notice.” Finally, the offer stated,

“If you accept this offer, your employment will be subject to the Company’s

personnel policies and practice, which will initially be substantially similar to

current Baylor policies.”

Following the creation of the joint venture in 2015, Perthuis worked for

BMGL as the Vice President of Sales and Marketing. He procured sales from

several companies by securing what the parties referred to as “channel partners”—

companies that agreed to purchase large volumes of genetic tests from BMGL

under long-term contracts. For example, in 2015, Perthuis participated in

negotiating a Laboratory Services Agreement (LSA) on behalf of BMGL with a

company called Natera. The LSA provided that Natera would use its own sales

staff to sell the tests under its own brand, and BMGL would provide “analytical

services,” or processing of genetic specimens. The LSA further provided that

BMGL would meet certain obligations regarding the formatting of test results and

timing for reporting certain test results. Natera agreed to pay an “exclusivity fee”

in exchange for BMGL’s agreement not to perform certain genetic tests for

Natera’s direct competitors, and Natera was obligated to meet minimum purchase

3 requirements to maintain this exclusivity. Natera also agreed to make a “pre-

payment” of $1,000,000 for anticipated analytical services. The LSA stated that if

the agreement was terminated by either party prior to Natera “ordering and taking

delivery of $1,000,000 of Analytical Services, BMGL shall refund to Natera the

remaining balance of the $1,000,000 pre-payment.” The LSA further provided that

BMGL would be obligated to refund the exclusivity fee if it terminated the

agreement within twelve months of the agreement’s effective date. The LSA set

out terms for generating purchase orders, pricing for various genetic tests that

varied depending on volume, invoicing and payment, and billing.

Perthuis testified that he did not receive any commission when the LSA was

signed; rather, he collected commissions on sales made to Natera under this LSA

throughout 2015 and 2016. He testified that BMGL calculated commissions

quarterly based on the revenue from tests that had been ordered, performed, and

billed to the proper account. He further explained that commissions were

determined by totaling his revenue for a particular quarter, adjusting that amount

for “bad debt” or particular clients’ failure to pay 100% of their bills, and then

multiplying that by his commission percentage.

In the fall of 2016, Perthuis was involved in negotiating a second

amendment and extension of the Natera LSA. By the end of 2016, the negotiations

on the amendment were nearing completion, and all material terms were in place

4 by early January 2017. BMGL then terminated Perthuis on January 23, 2017. The

next day, on January 24, 2017, BMGL signed the amended Natera LSA with an

effective date of January 30, 2017.

The Second Amended LSA added a new section, obligating BMGL to

“develop and validate a non-invasive prenatal multi-gene sequencing screen”

called “PreSeek.” The Second Amended LSA also adjusted the terms for payment

of “undisputed invoices,” set out terms for exclusivity and prepayment of fees

related to the PreSeek screening tests, and added new provisions regarding the

minimum purchase requirements set out in previous LSAs. Natera purchased tests

and analytical services under this contract after it became effective on January 30,

2017. Because Perthuis had been terminated, other BMGL personnel provided

services to Natera. Just a few months after Perthuis’s termination, BMGL

personnel negotiated a Third Amendment to the Natera LSA without Perthuis’s

participation and that amendment became effective on April 3, 2017. Other

companies, including Progenity, Fleury, and NIPT, were similarly recruited by

Perthuis while he worked for BMGL and then continued to make purchases from

BMGL after he was terminated by BMGL in January 2017 and eventually went to

work for one of BMGL’s direct competitors.

At trial, BMGL asserted that the commission agreement in the Employment

Offer Letter entitled Perthuis to a commission on his net sales and that he was only

5 entitled to commissions while he was employed by the company. It presented

evidence that, following his termination, it paid him commission due on his sales

through his last day. For example, an email sent by Perthuis on the day he was

terminated stated, “My offer says I get 3.5% of my sales. I have sold during these

20+ days in January. Can you please make sure this payment is included?” Perthuis

then testified that BMGL paid him commissions “until January 23rd,” but it did not

pay anything after his termination on January 23, 2017.

Perthuis asserted at trial that he was the procuring cause of all sales to

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Texas Farm Bureau Mutual Insurance Co. v. Sturrock
146 S.W.3d 123 (Texas Supreme Court, 2004)
Valence Operating Co. v. Dorsett
164 S.W.3d 656 (Texas Supreme Court, 2005)
Frost National Bank v. L & F Distributors, Ltd.
165 S.W.3d 310 (Texas Supreme Court, 2005)
Bed, Bath & Beyond, Inc. v. Urista
211 S.W.3d 753 (Texas Supreme Court, 2006)
Ford Motor Co. v. Ledesma
242 S.W.3d 32 (Texas Supreme Court, 2007)
Thota v. Young
366 S.W.3d 678 (Texas Supreme Court, 2012)
Ramesh v. Johnson
681 S.W.2d 256 (Court of Appeals of Texas, 1984)
Tenneco Inc. v. Enterprise Products Co.
925 S.W.2d 640 (Texas Supreme Court, 1996)
Frady v. May
23 S.W.3d 558 (Court of Appeals of Texas, 2000)
Grohman v. Kahlig
318 S.W.3d 882 (Texas Supreme Court, 2010)
Green International, Inc. v. Solis
951 S.W.2d 384 (Texas Supreme Court, 1997)
METAL STRUCTURES CORPORATION v. Bigham
347 S.W.2d 270 (Court of Appeals of Texas, 1961)
HECI Exploration Co. v. Neel
982 S.W.2d 881 (Texas Supreme Court, 1999)
Continental Casualty Co. v. Baker
355 S.W.3d 375 (Court of Appeals of Texas, 2011)
Francis v. Foster
260 S.W. 1023 (Texas Supreme Court, 1924)
Goodwin v. Gunter
185 S.W. 295 (Texas Supreme Court, 1917)

Cite This Page — Counsel Stack

Bluebook (online)
Baylor Miraca Genetics Laboratories, LLC v. Thomas Brandon Perthuis, Counsel Stack Legal Research, https://law.counselstack.com/opinion/baylor-miraca-genetics-laboratories-llc-v-thomas-brandon-perthuis-texapp-2020.